Illumina (NASDAQ:ILMN) had its price target boosted by equities researchers at Morgan Stanley from $122.00 to $135.00 in a note issued to investors on Thursday. The firm currently has an “underweight” rating on the life sciences company’s stock. Morgan Stanley’s price target indicates a potential downside of 37.66% from the company’s current price.

A number of other research analysts have also weighed in on the company. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $252.00 target price on the stock in a report on Tuesday, December 5th. Citigroup boosted their target price on Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday, October 25th. Barclays boosted their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Finally, Bank of America boosted their target price on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $202.60.

Illumina (ILMN) opened at $216.55 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The firm has a market capitalization of $30,784.10, a P/E ratio of 61.65, a P/E/G ratio of 3.48 and a beta of 0.79. Illumina has a 1-year low of $126.18 and a 1-year high of $230.72.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm’s revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 EPS. analysts anticipate that Illumina will post 3.75 earnings per share for the current fiscal year.

In other Illumina news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total value of $29,323.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Oene Mark Van sold 1,232 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $207.78, for a total value of $255,984.96. Following the completion of the transaction, the senior vice president now directly owns 11,691 shares of the company’s stock, valued at approximately $2,429,155.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 136,421 shares of company stock valued at $28,489,101. 0.89% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of ILMN. Winslow Capital Management LLC acquired a new position in Illumina in the 2nd quarter worth about $211,584,000. HPM Partners LLC increased its holdings in Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after purchasing an additional 749,424 shares in the last quarter. Fred Alger Management Inc. increased its holdings in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after purchasing an additional 548,030 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares in the last quarter. Finally, Capital World Investors increased its holdings in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after purchasing an additional 410,000 shares in the last quarter. 91.75% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/illumina-ilmn-pt-raised-to-135-00/1767461.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.